Is osteoporosis screening in postmenopausal women effective?

MOspace/Manakin Repository

Breadcrumbs Navigation

Is osteoporosis screening in postmenopausal women effective?

Please use this identifier to cite or link to this item: http://hdl.handle.net/10355/2947

[+] show full item record


Title: Is osteoporosis screening in postmenopausal women effective?
Author: Phillips, John; Krist, Alex; Wilder, Laura
Keywords: therapy
fracture risk
bone mineral density
screening interval
Date: 2003-04
Publisher: Family Physicians Inquiries Network
Citation: Journal of Family Practice, 52(4) 2003: 331-333.
Abstract: No single study evaluates the effectiveness of osteoporosis screening. However, screening women over the age of 65 years—or those between 60-64 years with certain risk factors—is recommended based on available evidence. First, osteoporosis is common, and its prevalence increases with age (strength of recommendation [SOR]: A—prospective cohort studies). Second, low bone mineral density predicts fracture risk (SOR: A—prospective cohort studies). Finally, the likelihood of osteoporotic fracture is reduced with therapy, such as alendronate 10 mg/day or risedronate 5 mg/day plus adequate daily calcium and vitamin D (SOR: A—meta-analysis of randomized clinical trials). Women under 60 years should not be screened (SOR: B—clinical decision rule). There is no evidence to guide decisions about screening interval or at what age to stop screening. The long-term risks of newer medications used for osteoporosis are unknown.
URI: http://hdl.handle.net/10355/2947

This item appears in the following Collection(s)

[+] show full item record